Harrow closes $30M cash acquisition of TYRVAYA from Viatris, up to $70M in sales milestones

HARROW, INC.

Paid Viatris $30.0M cash at closing, funded with cash on hand; up to $70M in contingent milestones tied to TYRVAYA net sales through Dec 31, 2029; total potential consideration $100M.
Harrow acquired worldwide TYRVAYA rights except Japan; Viatris kept Japan commercialization rights and will pay Harrow tiered royalties on Japanese net sales.
TYRVAYA is the first and only FDA-approved nasal spray for dry eye disease; approved in U.S., China and Taiwan, with marketing applications pending in additional markets.
About 40 experienced Viatris personnel with TYRVAYA and dry eye knowledge are expected to join Harrow's Ocular Surface commercial team in Q4 2026.
Harrow expects TYRVAYA to contribute more than $30 million in revenue in 2027; product complements VEVYE in the dry eye franchise and both use PhilRx pharmacy.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.